Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Observational cohort study on the prevention of venous thromboembolic events after elective orthopaedic surgery for Total Knee Replacement or Total Hip Replacement iin patients treated with PRADAXA to evaluate the efficacy ant safety of Pradaxa in real-life conditions
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| All comers |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Occurrence of Symptomatic Venous Thromboembolic Events | Occurrence of symptomatic venous thromboembolic (VTE) events in patients treated with Pradaxa (dabigatran etexilate) after orthopaedic surgery (either Total Hip Replacement (THR) or Total Knee Replacement surgery (TKR)). Symptomatic VTE events were defined as a confirmed proximal or distal deep vein thrombosis (DVT) or a confirmed pulmonary embolism (PE). | 11 weeks |
| Occurrence of Major Bleeding Events | Occurrence of major bleeding events (MBEs) in patients treated with Pradaxa (dabigatran etexilate) after orthopaedic surgery (either THR or TKR surgery). MBEs were defined as any fatal haemorrhage, any overt bleeding greater than could be expected combined with a loss of haemoglobin ≥ 2 g/dL or requiring transfusion ≥ 2 packed red blood cells units (PRBC), any symptomatic retroperitoneal, intracranial, intraocular or intraspinal haemorrhage or any bleeding requireing treatment cessation or reoperation. a confirmed proximal or distal deep vein thrombosis (DVT) or a confirmed pulmonary emboliam (PE). | 11 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| Dosage of Pradaxa at Initiation | Baseline | |
| Duration Between Surgery and First Dose of Pradaxa | 11 weeks | |
| Duration of Treatment |
Not provided
Inclusion criteria:
Exclusion criteria:
Not provided
Not provided
Not provided
Demographic, medical and chirurgical characteristics
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Boehringer Ingelheim | Boehringer Ingelheim | Study Chair |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Investigational Site 30 | Angers | France | ||||
| Boehringer Ingelheim Investigational Site 41 |
Not provided
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Total Knee Replacement | Patients undergoing elective total knee replacement (TKR) received a dose of dabigatran etexilate; the administered treatment was based on usual practice in a real-life setting. |
| FG001 | Total Hip Replacement |
| Title | Milestones | Reasons Not Completed | |||||
|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
Not provided
Not provided
| 11 weeks |
| Proportion of Patients With a Preoperative ALT Measurement | 11 weeks |
| Adherence to Treatment | The adherence to treatment was measured by patient declaration. | 11 weeks |
| Concomitant Treatments | Concomitant treatments prescribed at hospital discharge. | 11 weeks |
| Number of Patients Who Switched to Another Anticoagulant Therapy | Treated population included patients who took at least one dose of Pradaxa. One additional patient was excluded from the analysis as they were missing their date of first dose. | 11 weeks |
| Prescription for the Surveillance of the Platelet Count on the Day of Hospital Discharge | 11 weeks |
| Prescription for Nursing Care and Nurse Visits on the Day of Hospital Discharge | 11 weeks |
| Reasons for Nurse Visits on the Day of Hospital Discharge | 11 weeks |
| Frequency of Nurse Visits on the Day of Hospital Discharge | 11 weeks |
| Duration of Unplanned Hospitalizations at Visit 3 | 11 weeks |
| Reasons for Unplanned Hospitalizations at Visit 3 | 11 weeks |
| Reasons for Usual Follow-up | 11 weeks |
| Arles |
| France |
| Boehringer Ingelheim Investigational Site 40 | Beauvais | France |
| Boehringer Ingelheim Investigational Site 2 | Berck | France |
| Boehringer Ingelheim Investigational Site 25 | Bordeaux | France |
| Boehringer Ingelheim Investigational Site 45 | Boulogne-sur-Mer | France |
| Boehringer Ingelheim Investigational Site 13 | Bruay-la-Buissière | France |
| Boehringer Ingelheim Investigational Site 42 | Cahors | France |
| Boehringer Ingelheim Investigational Site 50 | Castelnau-le-Lez | France |
| Boehringer Ingelheim Investigational Site 36 | Chantilly | France |
| Boehringer Ingelheim Investigational Site 35 | Châteaubernard | France |
| Boehringer Ingelheim Investigational Site 10 | Châteaubriant | France |
| Boehringer Ingelheim Investigational Site 9 | Clinique Des Maussins-Paris | France |
| Boehringer Ingelheim Investigational Site 44 | Dole | France |
| Boehringer Ingelheim Investigational Site 3 | Dracy-le-Fort | France |
| Boehringer Ingelheim Investigational Site 46 | Haguenau | France |
| Boehringer Ingelheim Investigational Site 33 | Illkirch-Graffenstaden | France |
| Boehringer Ingelheim Investigational Site 23 | La Roche-sur-Yon | France |
| Boehringer Ingelheim Investigational Site 22 | Lannion | France |
| Boehringer Ingelheim Investigational Site 27 | Le Blanc Menil | France |
| Boehringer Ingelheim Investigational Site 31 | Le Port-Marly | France |
| Boehringer Ingelheim Investigational Site 21 | Libourne | France |
| Boehringer Ingelheim Investigational Site 5 | Lille | France |
| Boehringer Ingelheim Investigational Site 19 | Lyon | France |
| Boehringer Ingelheim Investigational Site 47 | Marcq En Bareuil | France |
| Boehringer Ingelheim Investigational Site 12 | Mâcon | France |
| Boehringer Ingelheim Investigational Site 28 | Mérignac | France |
| Boehringer Ingelheim Investigational Site 26 | Morlaix | France |
| Boehringer Ingelheim Investigational Site 48 | Nancy | France |
| Boehringer Ingelheim Investigational Site 7 | Nancy | France |
| Boehringer Ingelheim Investigational Site 8 | Nice | France |
| Boehringer Ingelheim Investigational Site 11 | Paris | France |
| Boehringer Ingelheim Investigational Site 17 | Paris | France |
| Boehringer Ingelheim Investigational Site 6 | Paris | France |
| Boehringer Ingelheim Investigational Site 24 | Perpignan | France |
| Boehringer Ingelheim Investigational Site 49 | Ploemeur | France |
| Boehringer Ingelheim Investigational Site 14 | Poissy | France |
| Boehringer Ingelheim Investigational Site 39 | Pontarlier | France |
| Boehringer Ingelheim Investigational Site 43 | Pringy | France |
| Boehringer Ingelheim Investigational Site 15 | Reims | France |
| Boehringer Ingelheim Investigational Site 20 | Rennes | France |
| Boehringer Ingelheim Investigational Site 53 | Saint Colombe Les Viennes | France |
| Boehringer Ingelheim Investigational Site 52 | Saint-Georges-de-Didonne | France |
| Boehringer Ingelheim Investigational Site 4 | Saint-Grégoire | France |
| Boehringer Ingelheim Investigational Site 18 | Saint-Priest-en-Jarez | France |
| Boehringer Ingelheim Investigational Site 32 | Saint-Priest-en-Jarez | France |
| Boehringer Ingelheim Investigational Site 51 | Saint-Saulve | France |
| Boehringer Ingelheim Investigational Site 37 | Saumur | France |
| Boehringer Ingelheim Investigational Site 34 | Semur-en-Auxois | France |
| Boehringer Ingelheim Investigational Site 1 | Strasbourg | France |
| Boehringer Ingelheim Investigational Site 38 | Toulouse | France |
| Boehringer Ingelheim Investigational Site 29 | Tourcoing | France |
| Boehringer Ingelheim Investigational Site 16 | Villeneuve-sur-Lot | France |
Patients undergoing elective total hip replacement (THR) received a dose of dabigatran etexilate; the administered treatment was based on usual practice in a real-life setting.
| COMPLETED |
|
| NOT COMPLETED |
|
|
Treated population included patients who took at least one dose of Pradaxa. One additional patient was excluded from the analysis as they were missing their date of first dose.
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Total Knee Replacement | Patients undergoing elective total knee replacement (TKR) received a dose of dabigatran etexilate; the administered treatment was based on usual practice in a real-life setting. |
| BG001 | Total Hip Replacement | Patients undergoing elective total hip replacement (THR) received a dose of dabigatran etexilate; the administered treatment was based on usual practice in a real-life setting. |
| BG002 | Total | Total of all reporting groups |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean | Standard Deviation | years |
| |||||||||||||||
| Sex: Female, Male | Count of Participants | Participants |
| ||||||||||||||||
| Creatinine clearance | Mean | Standard Deviation | mL/min |
| |||||||||||||||
| Weight | Mean | Standard Deviation | kilogramm |
| |||||||||||||||
| Height | Mean | Standard Deviation | cm |
| |||||||||||||||
| Participants with a Alanine Aminotransferase (ALT) of >2x normal upper limit | Number | participants |
| ||||||||||||||||
| Participants with at least one thromboembolic risk factor | Number | participants |
| ||||||||||||||||
| Participants with at least one cardiovascular risk factor | Number | participants |
| ||||||||||||||||
| Participants with at least one concomitant disease | Number | participants |
| ||||||||||||||||
| Previous treatment | Number | participants |
| ||||||||||||||||
| Current treatment | Number | participants |
| ||||||||||||||||
| Type of orthopedic surgery | Number | participants |
| ||||||||||||||||
| Indication for the surgery | Number | participants |
| ||||||||||||||||
| Duration of the surgery | Mean | Standard Deviation | minutes |
| |||||||||||||||
| Type of anesthesia | Number | participants |
|
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Occurrence of Symptomatic Venous Thromboembolic Events | Occurrence of symptomatic venous thromboembolic (VTE) events in patients treated with Pradaxa (dabigatran etexilate) after orthopaedic surgery (either Total Hip Replacement (THR) or Total Knee Replacement surgery (TKR)). Symptomatic VTE events were defined as a confirmed proximal or distal deep vein thrombosis (DVT) or a confirmed pulmonary embolism (PE). | Treated population included patients who took at least one dose of Pradaxa. One additional patient was excluded from the analysis as they were missing their date of first dose. | Posted | Number | participants | 11 weeks |
|
|
| |||||||||||||||||||||||||||||
| Primary | Occurrence of Major Bleeding Events | Occurrence of major bleeding events (MBEs) in patients treated with Pradaxa (dabigatran etexilate) after orthopaedic surgery (either THR or TKR surgery). MBEs were defined as any fatal haemorrhage, any overt bleeding greater than could be expected combined with a loss of haemoglobin ≥ 2 g/dL or requiring transfusion ≥ 2 packed red blood cells units (PRBC), any symptomatic retroperitoneal, intracranial, intraocular or intraspinal haemorrhage or any bleeding requireing treatment cessation or reoperation. a confirmed proximal or distal deep vein thrombosis (DVT) or a confirmed pulmonary emboliam (PE). | Treated population included patients who took at least one dose of Pradaxa. One additional patient was excluded from the analysis as they were missing their date of first dose. | Posted | Number | participants | 11 weeks |
| |||||||||||||||||||||||||||||||
| Secondary | Dosage of Pradaxa at Initiation | Treated population included patients who took at least one dose of Pradaxa. One additional patient was excluded from the analysis as they were missing their date of first dose. | Posted | Number | participants | Baseline |
|
| |||||||||||||||||||||||||||||||
| Secondary | Duration Between Surgery and First Dose of Pradaxa | Treated population included patients who took at least one dose of Pradaxa. One additional patient was excluded from the analysis as they were missing their date of first dose. | Posted | Mean | Standard Deviation | hours | 11 weeks |
|
| ||||||||||||||||||||||||||||||
| Secondary | Duration of Treatment | Treated population included patients who took at least one dose of Pradaxa. One additional patient was excluded from the analysis as they were missing their date of first dose. | Posted | Mean | Standard Deviation | days | 11 weeks |
|
| ||||||||||||||||||||||||||||||
| Secondary | Proportion of Patients With a Preoperative ALT Measurement | Treated population included patients who took at least one dose of Pradaxa. One additional patient was excluded from the analysis as they were missing their date of first dose. | Posted | Number | percentage of participants | 11 weeks |
|
| |||||||||||||||||||||||||||||||
| Secondary | Adherence to Treatment | The adherence to treatment was measured by patient declaration. | Treated population included patients who took at least one dose of Pradaxa. One additional patient was excluded from the analysis as they were missing their date of first dose. | Posted | Mean | Standard Deviation | percent | 11 weeks |
|
| |||||||||||||||||||||||||||||
| Secondary | Concomitant Treatments | Concomitant treatments prescribed at hospital discharge. | Treated population included patients who took at least one dose of Pradaxa. One additional patient was excluded from the analysis as they were missing their date of first dose. | Posted | Number | participants | 11 weeks |
|
| ||||||||||||||||||||||||||||||
| Secondary | Number of Patients Who Switched to Another Anticoagulant Therapy | Treated population included patients who took at least one dose of Pradaxa. One additional patient was excluded from the analysis as they were missing their date of first dose. | Posted | Number | participants | 11 weeks |
|
| |||||||||||||||||||||||||||||||
| Secondary | Prescription for the Surveillance of the Platelet Count on the Day of Hospital Discharge | Treated population included patients who took at least one dose of Pradaxa. One additional patient was excluded from the analysis as they were missing their date of first dose. | Posted | Number | participants | 11 weeks |
|
| |||||||||||||||||||||||||||||||
| Secondary | Prescription for Nursing Care and Nurse Visits on the Day of Hospital Discharge | Treated population included patients who took at least one dose of Pradaxa. One additional patient was excluded from the analysis as they were missing their date of first dose. | Posted | Number | participants | 11 weeks |
|
| |||||||||||||||||||||||||||||||
| Secondary | Reasons for Nurse Visits on the Day of Hospital Discharge | Treated population included patients who took at least one dose of Pradaxa. One additional patient was excluded from the analysis as they were missing their date of first dose. | Posted | Number | participants | 11 weeks |
|
| |||||||||||||||||||||||||||||||
| Secondary | Frequency of Nurse Visits on the Day of Hospital Discharge | Treated population included patients who took at least one dose of Pradaxa. One additional patient was excluded from the analysis as they were missing their date of first dose. | Posted | Mean | Standard Deviation | times per week | 11 weeks |
|
| ||||||||||||||||||||||||||||||
| Secondary | Duration of Unplanned Hospitalizations at Visit 3 | Outcome measure was not analyzed. | Posted | 11 weeks |
|
| |||||||||||||||||||||||||||||||||
| Secondary | Reasons for Unplanned Hospitalizations at Visit 3 | Outcome measure was not analyzed. | Posted | 11 weeks |
|
| |||||||||||||||||||||||||||||||||
| Secondary | Reasons for Usual Follow-up | Treated population included patients who took at least one dose of Pradaxa. One additional patient was excluded from the analysis as they were missing their date of first dose. | Posted | Number | participants | 11 weeks |
|
|
11 weeks
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Total Knee Replacement | Patients undergoing elective total knee replacement (TKR) received a dose of dabigatran etexilate; the administered treatment was based on usual practice in a real-life setting. | 48 | 746 | 0 | 746 | ||
| EG001 | Total Hip Replacement | Patients undergoing elective total hip replacement (THR) received a dose of dabigatran etexilate; the administered treatment was based on usual practice in a real-life setting. | 37 | 929 | 0 | 929 |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Anaemia | Blood and lymphatic system disorders | MEDDRA 15.1 | Systematic Assessment |
| |
| Coagulopathy | Blood and lymphatic system disorders | MEDDRA 15.1 | Systematic Assessment |
| |
| Atrial fibrillation | Cardiac disorders | MEDDRA 15.1 | Systematic Assessment |
| |
| Cardiac failure | Cardiac disorders | MEDDRA 15.1 | Systematic Assessment |
| |
| Myocardial infarction | Cardiac disorders | MEDDRA 15.1 | Systematic Assessment |
| |
| Abdominal strangulated hernia | Gastrointestinal disorders | MEDDRA 15.1 | Systematic Assessment |
| |
| Colonic stenosis | Gastrointestinal disorders | MEDDRA 15.1 | Systematic Assessment |
| |
| Gastrointestinal haemorrhage | Gastrointestinal disorders | MEDDRA 15.1 | Systematic Assessment |
| |
| Haematemesis | Gastrointestinal disorders | MEDDRA 15.1 | Systematic Assessment |
| |
| Intestinal obstruction | Gastrointestinal disorders | MEDDRA 15.1 | Systematic Assessment |
| |
| Large intestine perforation | Gastrointestinal disorders | MEDDRA 15.1 | Systematic Assessment |
| |
| Melaena | Gastrointestinal disorders | MEDDRA 15.1 | Systematic Assessment |
| |
| Pancreatitis acute | Gastrointestinal disorders | MEDDRA 15.1 | Systematic Assessment |
| |
| Rectal ulcer | Gastrointestinal disorders | MEDDRA 15.1 | Systematic Assessment |
| |
| Asthenia | General disorders | MEDDRA 15.1 | Systematic Assessment |
| |
| Death | General disorders | MEDDRA 15.1 | Systematic Assessment |
| |
| Device dislocation | General disorders | MEDDRA 15.1 | Systematic Assessment |
| |
| Impaired healing | General disorders | MEDDRA 15.1 | Systematic Assessment |
| |
| Malaise | General disorders | MEDDRA 15.1 | Systematic Assessment |
| |
| Device related infection | Infections and infestations | MEDDRA 15.1 | Systematic Assessment |
| |
| Device related sepsis | Infections and infestations | MEDDRA 15.1 | Systematic Assessment |
| |
| Infection | Infections and infestations | MEDDRA 15.1 | Systematic Assessment |
| |
| Postoperative wound infection | Infections and infestations | MEDDRA 15.1 | Systematic Assessment |
| |
| Septic shock | Infections and infestations | MEDDRA 15.1 | Systematic Assessment |
| |
| Subcutaneous abscess | Infections and infestations | MEDDRA 15.1 | Systematic Assessment |
| |
| Fall | Injury, poisoning and procedural complications | MEDDRA 15.1 | Systematic Assessment |
| |
| Femur fracture | Injury, poisoning and procedural complications | MEDDRA 15.1 | Systematic Assessment |
| |
| Hip fracture | Injury, poisoning and procedural complications | MEDDRA 15.1 | Systematic Assessment |
| |
| Joint dislocation | Injury, poisoning and procedural complications | MEDDRA 15.1 | Systematic Assessment |
| |
| Joint dislocation postoperative | Injury, poisoning and procedural complications | MEDDRA 15.1 | Systematic Assessment |
| |
| Operative haemorrhage | Injury, poisoning and procedural complications | MEDDRA 15.1 | Systematic Assessment |
| |
| Patella fracture | Injury, poisoning and procedural complications | MEDDRA 15.1 | Systematic Assessment |
| |
| Post procedural haematoma | Injury, poisoning and procedural complications | MEDDRA 15.1 | Systematic Assessment |
| |
| Post procedural haemorrhage | Injury, poisoning and procedural complications | MEDDRA 15.1 | Systematic Assessment |
| |
| Scapula fracture | Injury, poisoning and procedural complications | MEDDRA 15.1 | Systematic Assessment |
| |
| Wound dehiscence | Injury, poisoning and procedural complications | MEDDRA 15.1 | Systematic Assessment |
| |
| Hyponatraemia | Metabolism and nutrition disorders | MEDDRA 15.1 | Systematic Assessment |
| |
| Arthralgia | Musculoskeletal and connective tissue disorders | MEDDRA 15.1 | Systematic Assessment |
| |
| Joint stiffness | Musculoskeletal and connective tissue disorders | MEDDRA 15.1 | Systematic Assessment |
| |
| Metastases to central nervous system | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MEDDRA 15.1 | Systematic Assessment |
| |
| Metastases to lung | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MEDDRA 15.1 | Systematic Assessment |
| |
| Neoplasm | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MEDDRA 15.1 | Systematic Assessment |
| |
| Pancreatic carcinoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MEDDRA 15.1 | Systematic Assessment |
| |
| Micturition disorder | Renal and urinary disorders | MEDDRA 15.1 | Systematic Assessment |
| |
| Renal failure | Renal and urinary disorders | MEDDRA 15.1 | Systematic Assessment |
| |
| Renal failure acute | Renal and urinary disorders | MEDDRA 15.1 | Systematic Assessment |
| |
| Urinary retention | Renal and urinary disorders | MEDDRA 15.1 | Systematic Assessment |
| |
| Acute pulmonary oedema | Respiratory, thoracic and mediastinal disorders | MEDDRA 15.1 | Systematic Assessment |
| |
| Hip arthroplasty | Surgical and medical procedures | MEDDRA 15.1 | Systematic Assessment |
| |
| Patellectomy | Surgical and medical procedures | MEDDRA 15.1 | Systematic Assessment |
| |
| Deep vein thrombosis | Vascular disorders | MEDDRA 15.1 | Systematic Assessment |
| |
| Femoral artery occlusion | Vascular disorders | MEDDRA 15.1 | Systematic Assessment |
| |
| Haematoma | Vascular disorders | MEDDRA 15.1 | Systematic Assessment |
| |
| Haemodynamic instability | Vascular disorders | MEDDRA 15.1 | Systematic Assessment |
| |
| Haemorrhage | Vascular disorders | MEDDRA 15.1 | Systematic Assessment |
| |
| Phlebitis | Vascular disorders | MEDDRA 15.1 | Systematic Assessment |
| |
| Phlebitis deep | Vascular disorders | MEDDRA 15.1 | Systematic Assessment |
| |
| Pulmonary embolism | Vascular disorders | MEDDRA 15.1 | Systematic Assessment |
| |
| Thrombophlebitis superficial | Vascular disorders | MEDDRA 15.1 | Systematic Assessment |
| |
| Thrombosis | Vascular disorders | MEDDRA 15.1 | Systematic Assessment |
| |
| Venous thrombosis | Vascular disorders | MEDDRA 15.1 | Systematic Assessment |
| |
| Venous thrombosis limb | Vascular disorders | MEDDRA 15.1 | Systematic Assessment |
|
Not provided
Data for the following secondary endpoints were not collected:
Medical appointments with a general practitioner or specialist at visit 3, Frequency of medical appointments at visit 3, Prescription received at visit 3.
Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Boehringer Ingelheim Call Center | Boehringer Ingelheim Pharmaceuticals | 1-800-243-0127 | clintriage.rdg@boehringer-ingelheim.com |
| ID | Term |
|---|---|
| D054556 | Venous Thromboembolism |
| ID | Term |
|---|---|
| D013923 | Thromboembolism |
| D016769 | Embolism and Thrombosis |
| D014652 | Vascular Diseases |
| D002318 | Cardiovascular Diseases |
Not provided
Not provided
| Male |
|
| Aspirin |
|
| Clopidogrel |
|
| Amiodarone |
|
| Hydroquindin |
|
| Verapimil |
|
| Aspirin |
|
| Clopidogrel |
|
| Amiodarone |
|
| Hydroquinidin |
|
| Verapamil |
|
| Repair of existing prothesis |
|
| Osteonecrosis |
|
| Post-trauma |
|
| Inflammatory arthritis |
|
| Other |
|
| Spinal |
|
| Epidural |
|
| Units | Counts |
|---|---|
| Participants |
|
|
|
|
|
|
|
|
|
|
|
|
|
|